Contract Recruiter
Rezolute Bio
Contract Recruiter
Rezolute Bio
Develops monoclonal antibodies for rare diseases
Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.
Position Summary
We are seeking an experienced Contract Recruiter for a 6 month contract to join our rapidly growing biopharmaceutical company during an exciting phase of expansion. This individual will play a critical role in attracting, engaging, and hiring top talent across a variety of functions, including Clinical Development, Regulatory Affairs, Medical Affairs, Biometrics, Research, CMC, Quality, Commercial, and Corporate Operations.
The ideal candidate brings a strong track record of full-cycle recruiting and sourcing within the biotechnology and pharmaceutical industries, is highly skilled at proactive sourcing and candidate engagement, and thrives in a fast-paced, high-growth environment. This role requires a hands-on recruiter who is equally comfortable developing talent pipelines, managing candidate relationships, and coordinating a seamless interview process.
This is a hybrid contract position requiring onsite presence three days per week.
Full-Cycle Recruitment
Talent Sourcing & Pipeline Development
Interview Coordination & Candidate Management
Recruiting Operations
Required
Preferred
Key Competencies
Work Environment
Rezolute (RZLT) currently anticipates the base salary for the Contract Recruiter role could range from $65.00 per hour to $90.00 per hour and will depend in part on the successful candidate’s qualifications for the role, including education and experience
Develops monoclonal antibodies for rare diseases
Rezolute Bio develops therapies for rare diseases, led by RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. RZ358 is a human monoclonal antibody that binds insulin to reduce its activity, aiming to lessen hypoglycemia, while RZ402 is an oral plasma kallikrein inhibitor for DME. The company differentiates itself by targeting rare, unmet-need conditions and pursuing late-stage candidates in both antibody and small-molecule formats. Its goal is to bring approved therapies to patients by advancing its programs through development to commercialization.
Explore more opportunities at Rezolute Bio